Introduction
In this ruling on trademark protection in the pharmaceutical sector, the Bombay High Court has granted an interim injunction to Sun Pharma against United Biotech’s use of a similar mark for the same medicine. The decision highlights the delicate balance courts must strike between protecting established brand goodwill and respecting long market use, especially when marks are derived from generic drug names. It also underscores the high threshold required to challenge a registered trademark at the interim stage.
Factual And Procedural Background
Sun Pharma Laboratories Limited, a major pharmaceutical company, claimed rights over the trademark “OCTRIDE” used for injections containing octreotide acetate, a drug prescribed for serious conditions like acromegaly and certain tumours. The company traced its rights back to the late 1990s through predecessors and asserted substantial sales and reputation across India and globally.
United Biotech Private Limited, another pharmaceutical manufacturer with exports to several countries, had been selling the same drug under the mark “OTIDE” for many years. Both marks are derived from the International Non-Proprietary Name (INN) of the active ingredient “Octreotide”. Sun Pharma filed a commercial intellectual property suit seeking an injunction against United Biotech for trademark infringement and passing off. An ex-parte ad-interim injunction was initially granted in July 2025, which United Biotech later challenged by filing an application to vacate it.
Key Parties In The Case
| Party | Role | Trademark Used |
|---|---|---|
| Sun Pharma Laboratories Limited | Plaintiff | “OCTRIDE” |
| United Biotech Private Limited | Defendant | “OTIDE” |
Important Legal Issues
- Trademark infringement in the pharmaceutical sector
- Protection of goodwill and reputation
- Use of marks derived from generic drug names
- Passing off claims
- Interim injunction standards under trademark law
Importance Of The Ruling
The ruling is significant because it demonstrates how courts approach disputes involving pharmaceutical trademarks that are partially derived from generic drug names. The judgment also reflects judicial caution in balancing public interest, established market presence, and trademark exclusivity in the healthcare industry.
Dispute Over “OCTRIDE” and “OTIDE” Trademarks
The core dispute centred on whether Sun Pharma could stop United Biotech from using “OTIDE”. Sun Pharma argued phonetic and visual similarity between “OCTRIDE” and “OTIDE” would cause confusion among doctors, pharmacists, and patients. It claimed prior adoption, registration, and extensive goodwill.
United Biotech countered that it had honestly adopted and used its mark since 1999 and obtained registration, and both marks had co-existed in the market for years without actual confusion. The defendant also raised issues of delay by Sun Pharma.
Reasoning and Analysis of the Judge
The court carefully examined the rival marks, their registrations, market use, and applicable legal principles. The judge noted that both parties hold trademark registrations, creating a situation where neither can easily claim exclusive rights against the other without strong grounds.
Court Findings on Infringement
On infringement, the court held that Sun Pharma failed to demonstrate that United Biotech’s registration was ex facie illegal or fraudulent. The judge referred to the high threshold laid down by the Full Bench of the Bombay High Court in Lupin Limited vs Johnson and Johnson MANU/MH/3536/2015.
Since both marks derive from the same generic molecule name, the registration could not be treated as shocking the conscience of the court.
Passing Off and Confusion Test
For passing off, the court applied the classic trinity test of:
- Goodwill
- Misrepresentation
- Damage
While acknowledging Sun Pharma’s sales and reputation, the judge found that United Biotech had been using its mark subsequent to Plaintiff. The court emphasised that in pharmaceutical cases, the threshold for confusion is lower due to public health concerns.
Important Precedents Discussed
The judge discussed several important precedents, including:
- Cadila Health Care Ltd vs Cadila Pharmaceuticals Ltd – on heightened scrutiny in pharma trademarks.
- Wander Ltd vs Antox India Pvt. Ltd [1990 Supp. SCC 727] – on balance of convenience.
- S. Syed Mohideen vs P. Sulochana Bai ((2016) 2 SCC 683) – on the irrelevance of fraudulent intent in passing off.
Final Decision of the Court
The Bombay High Court confirmed the interim injunction granted in the earlier order dated 29.07.2025.
Case Details
| Case Title | Sun Pharma Laboratories Limited v. United Biotech Private Limited |
|---|---|
| Date of Order | 4 May 2026 |
| Case Number | Interim Application (L) No. 19536 of 2025 in Commercial IP Suit (L) No. 19268 of 2025 |
| Neutral Citation | 2026:BHC-OS:11436 |
| Name of Court | High Court of Judicature at Bombay (Ordinary Original Civil Jurisdiction – Commercial Division) |
| Name of the Honourable Judge | Justice Sharmila U. Deshmukh |
